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Introduction
Only limited data are presently available
on the embryotoxic effects of 2,3,7,8-tetra-
chlorodibenzo-p-dioxin (TCDD). This is true
for the number of animals used per experi-
mental group, especially in the higher dose
range, as well as for the number of dif-
ferent species of experimental animals test-
ed. There has been an understandable re-
luctance to investigate these highly toxic
compounds, because of the hazards of con-
taminating animal quarters and the risk to
personnel. Nevertheless, we feel that the
data available allow a rough estimate of the
dangers that may be encountered with ex-
posure to such dioxins during pregnancy.
The possibility that TCDD might have cer-
tain types of embryotoxic effects was real-
ized for the first time when Courtney et al.
(1) reported their data on the teratogenic
effect of 2,4,5-T. Substances like TCDD have
been known for some time (2-4) to be con-
taminants of chlorinated phenols and deriva-
tives of such compounds and they were
thought to be responsible for an intoxication
called chloracne (5). Some commercial
samples of 2,4,5-T apparently were rather
highly contaminated with these extremely
toxic substances.
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In this paper we evaluate exclusively data
which have been obtained using pure TCDD.
No attempt is made to analyze the rather
extensive literature on results obtained with
2,4,5-T samples contaminated to various de-
grees with TCDD or similar compounds.
Some Special Aspects of Embryotoxic
Effects Induced by TCDD
Some General Aspects of Embryotoxic
Action
Considerable confusion has been caused by
many previous investigators with the nomen-
clature used in the field of prenatal toxi-
cology. Unfortunately, the term used to
specify certain experimental data in this
field may suggest a special mode of action
(6) and, more important, may trigger con-
clusions on a possible hazard to be expected
duringhuman embryonic development.
We, therefore, wish to suggest a system of
nomenclature used by our group which is
in accordance with the terms used in toxi-
cological research and which at the same
time takes into account the special situation
of prenatal development.
The most comprehensive term is embryo-
toxic (fetotoxic) effect. A special situation of
an embryotoxic effect may be characterized,
e.g., a teratogenic effect, an embryolethal
(fetolethal) effect, or a retardation (re-
tarded growth) etc.
We feel that the following definitions
prove to be convenient. By embryotoxic
(fetotoxic) effects we denote all transient or
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or fetus, regardless of the mechanism of
action. By embryolethal (fetolethal) effect
or embryomortality (or fetomortality) we
denote prenatal mortality at any stage of
embryonic or fetal development (may be
referred to as LD, - LD95). This term is
certainly not identical with embryotoxic but
refers to a special event that may occur in
the course of an embryotoxic action.
We define a teratogenic effect as an ab-
normality originating from an impairment
of an event typical for embryonic or fetal
development (induction process, differentia-
tion). The abnormality should be largely ir-
reversible. It may be obvious by macroscopic
appearance or "hidden" (micromorphological
defect or inborn error of metabolism) or
result in a mental abnormality.
Some examples of embryotoxic, not tera-
togenic effects are: general retardation of
embryonic (or fetal) growth, retarded oc-
currence of certain ossification centers (re-
versible), fetal intestinal hemorrhages
(without secondary effects). Representing
a teratogenic effect would be an irreversible
involution of lymphatic tissues (with conse-
quences in postnatal life) or a severe mental
defect resulting from an impairment of pre-
natal brain development.
Some Special Aspects Connected with the
Action of TCDD
A brief analysis of the effects of TCDD on
prenatal development may suggest that
TCDD is a surprisingly specific teratogen,
interfering only with a few special develop-
mental processes. An increased frequency of
cleft palate and kidney abnormalities of a
special type are the only teratogenic effects
which have been observed. Interestingly
enough, it has not been possible so far to
induce limb or head abnormalities with this
agent, despite the fact that the drug was
given at the "critical period" for the induc-
tion of such malformations. Larger experi-
mental series over a sufficient dose range
are necessary to permit conclusions on the
specificity of the teratogenic action of TCDD,
however.
TCDD is certainly not a teratogenic agent
exclusively, since an increased fetomortality
results if the drug is given at a high enough
dose over a long enough time interval, al-
though with such a dose schedule no obvious
symptoms of a maternal toxicity become
evident. Apparently the higher doses lead to
a more general toxic effect on the embryonic
cells, but an effect on the placenta or mater-
nal tissues cannot be excluded at the moment.
Some of the toxic signs which can be
demonstrated in the fetal tissue should not
be referred to as teratogenic. This includes
the intestinal hemorrhages (without per-
manent secondary changes), a fatty infiltra-
tion (Fig. 1) of fetal livers (7) (to our
knowledge not reported before with any em-
bryotoxic agent), as well as subcutaneous
edema and delayed ossification. Most of these
symptoms are reversible and they are cer-
tainly not the result of a typical interference
with developmental processes. It is interest-
ing that most of these symptoms can also
be demonstrated in tissues of adult organ-
isms under the toxic action of TCDD.
In adult mice a pronounced involution of
some lymphatic tissues can be demonstrated
as an early toxic sign, together with a loss
of weight (8), predominantly in a drastic
reduction of the size of the thymus, the
spleen, and lymph nodes (9). A similar in-
terference has been observed in our group
with the development of these systems dur-
ing fetal development in the presence of
TCDD (10). This impaired development of
lymphatic organs results in a typical post-
natal insufficiency and in a pronounced
reduction of the chances of postnatal sur-
vival.
Although these symptoms very much re-
semble changes produced in the adult organ-
ism by TCDD (9), we would consider these
embryotoxic effects as teratogenic, since a
typical developmental process is altered and
the defect can be demonstrated long enough
tohandicap the newborn.
From all our studies we have seen no
indication that the general growth of the
fetal mice showing a teratogenic effect was
affected to a significant degree.
Environmental Health Perspectives 68FIGURE 1. Example of an electron microscopic examination of fetal rat liver (day 18 of gestation). TCDD
(15 stg/kg) was given once on day 17 of pregnancy. Using TCDD it has been possible to produce a fatty
infiltration of the developing fetal liver as early as on day 14 of gestation.
We feel that the sort of embryotoxic ef-
fects induced by TCDD are very interesting
from a theoretical point of view and to
some extent unique. Therefore, they justify
a further, closer analysis.
Results and Discussion
First indications of embryotoxic effects of
TCDD were reported in 1970 by Sparschu
et al. (11, 12) from experiments with rats.
Further data on embryotoxic effects then
became available from reports of Courtney
and Moore (13) and from our group (14)
(see Table 1).
Three major effects were noted in these
studies: intestinal hemorrhages in rat fe-
tuses and an increased frequency of cleft
palate and kidney abnormalities in mouse
fetuses. Teratological studies with rats have
apparently only been performed using re-
peated doses of TCDD while with mice ef-
fects produced by single as well as by re-
peated doses of this drug have been re-
ported.
We shall try to evaluate the data from
teratological studies available and to supple-
ment them with unpublished data obtained
in our laboratory. The following aspects will
be discussed: (1) dose-response relationships
after repeated doses of TCDD given to rats
and mice; (2) dose-response relationships
after single doses of TCDD given to mice and
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TCDD in rats and mice.,
Dose /Ag/kg Time
Teratogenic TCDD
effect Minimal given,
Species Strain (system) tested -ED,0b days Route Reference
Rat Intestinal
hemorrhage 0.125 = 0.5 ? Oral Sparschu et al. (12)
CD Kidney 0.5 > 1 6-15 SC Courtney and Moore (13)
Mouse CD-I CP 1? >3 6-15 SC 3>
Kidney 13615 S abnormality 1 1-3 615 50
DBA/2J CP 3 > 3 6-15 SC
Kidney 3>3615 S abnormality 3 > 3 615 50
C57Bl/6J CP 3 > 3 6-15 SC
Kidney 3<3615 S abnormality < 3 615 50
NMRI CP 3 6.5 6-15 Oral Neubert and Dillmann
(14)
9 < 9 9-13 Oral "
15 40 13 Oral Neubert et al. (this paper)
5 15 11 Oral
a The smallest dose with which a significant teratogenic effect has been produced is indicated. Since
sometimes only one dose level was tested this does not necessarily give the smallest dose from which
a teratogenic effect could result. Routes were both oral and subcutaneous (SC). An attempt was also
made to estimate the EDso from the few data available.
bED,: dose required to produce effect in 50% of animals.
evaluation of phase specificity; (3) embryo-
toxic effects observed after application of
TCDD together with other teratogens.
Dose-Response Relationship of Teratogenic
Effects and Fetomortality After Repeated
Doses of TCDD to Rats or Mice
The first striking result which is immedi-
ately apparent is the extremely low dose of
TCDD which is able to induce teratogenic
and fetolethal effects in mice and rats. Al-
though these species must be considered to
be comparatively insensitive during the adult
status towards the toxic action of this com-
pound, repeated or even single doses of as
little as 1-10 jig/kg are capable of reproduc-
ibly triggering malformations of certain
types. This is by far the smallest effective
dose of any teratogen known today.
Interestingly, of the series of chlorinated
dibenzodioxins, the tetrachloro derivative ap-
parently is the most active one. The hexa-
chloro derivative also seems to show some
embryotoxic activity, while the dichloro and
the octachloro derivatives have been report-
ed (15) to be nonembryotoxic. The few data
available suggest that embryotoxic activity
is a property of those compounds having a
pronounced chloracne potency (15).
Teratogenic effects induced by TCDD-
Two major types of malformation have been
reported so far in fetuses of rats or mice
treated with TCDD during pregnancy: cleft
palate-so far reported only in mice-and
kidney abnormalities of a certain type, ob-
served in both species after single or re-
peated doses of TCDD (Table 2).
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Dose producing
-50% effect,
Species Abnormality ,Ag/kg e
Rat Intestinal hemorrhage 0.5 ?
Kidney abnormalities 1-2 ?
Lethal 1-2 ?
Mouse Cleft palate 6
Kidney abnormalities 1-3
Lethal 7
a TCDD was given on days 6-15 of pregnancy.
bLiterature data (11, 13, 14).
9? = no exact data available from the litera-
ture. Doses assumed to be in the range indi-
cated.
Furthermore, an involution of fetal thymus
and spleen and other lymphatic organs can
be observed (10) which affects the survival
after birth. Intestinal hemorrhage and fatty
infiltration of the fetal liver do not represent
teratogenic effects, as discussed above. With-
in the adult organism similar symptoms can
be noticed.
We are convinced that looking more closely
at fetuses affected by TCDD will reveal more
abnormalities; this has been the case with
every drug effect evaluated carefully enough
with the modern biochemical and micro-
morphological methods available.
Other than the reports on teratogenic and
embryotoxic effects produced by TCDD in
mice and rats with documented experimental
data we found only a few references which
suggest that embryotoxic effects may also
occur in other animal species after a treat-
ment with TCDD. Although we did not find
verifiable data, TCDD apparently can also
produce embryotoxic effects in hamsters. Eye
abnormalities and reduction of mean fetal
weight-neither of which is typical of symp-
toms seen in rats or mice after treatment with
TCDD-as well as gastrointestinal hemorr-
hages and increased prenatal mortality are
mentioned after doses of TCDD in the /Ag/
kg range for 5 days (16).
Unfortunately, we have no knowledge of
teratological experiments performed with the
highly TCDD-sensitive species guinea pig
and rabbit. It would be important to know
whether the comparatively high toxicity
seen in adult animals of these species is also
paralleled by a high degree of sensitivity of
the embryos or fetuses when compared with
that of rats and mice.
Fetomortality induced by TCDD-Al-
though the teratogenic effect induced by
TCDD seems to be rather specific because
the development of only a limited number of
special organ systems is found to be im-
paired, TCDD when given in multiple doses
does not represent an exclusively teratogen-
ic agent. The occurrence of developmental
abnormalities in chronic experiments is al-
most paralleled in a dose-response curve by
the fetomortality (Fig. 2). However, as in
many teratdlogical experiments, there is no
obligatory connection of these two para-
meters. In mice a high cleft palate frequency
can be obtained without any apparent feto-
mortality (Fig. 3), just by reducing the time
of treatment from 10 days (day 6-15) to
5 days (day 9-13 of gestation).
probit,%
pJgykgTCDD
FIGURE 2. Comparison of the teratogenic effect and
the degree of fetomortality induced by TCDD. The
effect of a single dose given on day 13 of preg-
nancy is compared with that resulting after re-
peated doses given during days 6-15 of pregnancy.
The points are derived from the evaluation of the
total fetuses per treated group of mice (at least
12 litters per dose). TCDD was given in rape-seed
oil by stomach tube once a day (1 P.M.). Cleft
palate frequency is evaluated in this experiment
as percent of the viable fetuses. Effect (probit
scale) is plotted against dose (log scale). The
control values represent 2000 fetuses from mice
treated with rape-seed oil for 10 days.
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FIGURE 3. Comparison of teratogenic effect and feto-
mortality produced by TCDD. Ten pregnant mice
each were treated with 9 /Lg/kg TCDD orally
during the time interval indicated. The numbers
of fetuses affected are given (M ± S.D.) per
litter. Average number of implantation sites per
litter was 11.5 (= 100%). Controls received rape-
seed oil only. CP denotes cleft palate frequency.
Differences among strains in the degree of
teratogenic and fetolethal effects induced by
TCDD in mice-Information on differences
in the susceptibility towards TCDD of dif-
ferent strains of experimental animals are
so far available only for mice, mainly
through the data of Courtney and Moore
(13). Tables 3 and 4 summarize these data,
supplemented by information obtained with
NMRI mice in our laboratory (14). For a
better comparison we have recalculated some
of the data. Since for half of the strains
data are only available at one dose, the com-
parison is made for the effect produced by
3 ug/kg TCDD given during days 6-15 of
gestation.
As can be seen from Table 3, with this
scheme of treatment a noticible but small
fetomortality occurs only with the CD-1
mice. With the same scheme of treatment
a significant increase in the cleft palate fre-
quency over that of the controls can be ob-
served with all of the four strains tested.
While the incidence of this type of teratogen-
ic effect is roughly the same with three of
the four strains (3-4%), the C57BI mice
are clearly more susceptible to the teratogen.
Further data of Courtney and Moore (13)
lead to the conclusion that the special sensi-
tivity of the C57BI mice also holds for
the induction of kidney abnormalities. At
the moment no clue is available for the cause
of this higher sensitivity. An increased sus-
ceptibility of the target tissue or alterna-
tively a special rate of drug metabolism in
this strain, leading to a higher concentration
of the effective drug in the fetus, may be
responsible for this special sensitivity. Fur-
'ther data are needed to distinguish be-
tweenthese possibilities.
Dose-Response Relationship of Teratogenic
Effects and Fetomortality in Mice after a
Single Dose of TCDD (Phase Specificity)
We have started some systematic studies
to clarify the question whether the terato-
genic effects may be induced by single doses
of TCDD-and by what doses-and what ap-
pears to be the most sensitive interval of
fetal development. The induction of cleft
palates was chosen as a criterion in these
studies, but other types of malformation
(kidney abnormalities) may also be evaluat-
ed from these experimental series.
The highest degree of malformations can
be produced (14) when the drug is given to
the mice on day I1 of pregnancy. Although
a significant increase in the cleft palate fre-
quency over that of the controls can also be
induced by giving the teratogen on days
10 or 12 of gestation, the effect obtained on
these days is only about half of that pro-
duced on day 11 for a given strain.
Environmental Health Perspectives 72Table 3. Fetomortality induced by TCDD in different
strains of mice.a
Avg. fetomortality, %v/litter
Mouse strain TCDD Controls
CD-1 i 12.4 (144) 8.6
NMRI d 5.3 (110) 4.8
DBA e 27.0 (103) 26.1
C57BI e 5.3 (49) 10.8
a TCDD, 3 utg/kg, was given daily on days 6-15
of pregnancy.
b Values in parentheses denote percentage when
compared with the corresponding controls re-
ceiving the vehicle only. In none of the strains
tested was a pronounced fetomortality ob-
served.
eTCDD given subcutaneously (SC) in DMSO;
data of Courtney and Moore (13).
dTCDD given orally in oil; data of Neubert and
Dillmann (14).
When TCDD is given on day 13 of gesta-
tion, an effect of only about one third of that
seen on day 11 is produced. It should be
mentioned that in all of these experiments
only one time per day (at noon) was checked
since it was not intended to pinpoint exactly
the time of the highest sensitivity. The maxi-
mum of the effect may, therefore, be some-
what higher.
In order to compare the cleft palate-induc-
ing effect of TCDD with that seen after treat-
ment of pregnant mice with other teratogens
we have performed most of the following
experiments by giving TCDD on day 13 of
gestation, even though the effect with TCDD
obtained on this day is not maximal. Interest-
ingly enough, cleft palates can be produced
by giving different teratogens with a phase
optimum which varies considerably, indicat-
ing quite different modes of action of the
various teratogens (Fig. 4).
Because of our interest in the dose-re-
sponse relationship of the teratogenic effect
of TCDD we compared the dose-response
curves (cleft palate frequency) obtained with
five cleft palate-inducing drugs (Fig. 5). The
steepness of the dose-response curves varies
considerably when the different drugs are
13 14
day of gestation
FIGURE 4. Phase specificity of cleft palate induction
by various drugs. A rough survey is given on the
optimal effect produced by different teratogens.
The points are taken from large experimental se-
ries performed in our laboratory with NMRI
mice. 100%/ indicates the maximum effect, not a
cleft palate frequency of 100%. The arrow indi-
cates the time at which most of our combination
experiments have been performed. Not all tera-
togens exhibit their maximal effect at this stage
of development.
Table 4. Cleft palate frequency induced by TCDD in different strains of mice.&
TCDD Controls
Mouse Fetuses Affected Affected
strain evaluated CP, % b litters (%) CP, t b litters (%)
CD-1 c 104 3 3/10 (30) < 0.3 0/29 (< 3)
DBAt 55 4 2/9 (22) < 1 0/23 (< 4)
NMRId 271 3 7/24 (29) 0.7 10/160 (6)
C57B1 e 58 22 5/7 (71) < 1 0/23 (< 4)
a TCDD, 3 Ag/kg, was given daily during days 6-15 of pregnancy (same experimental conditions as in
Table 3). Strain C57BI appears to be the most susceptible strain. All the other strains tested show
about the same degree of sensitivity.
b % CP = percentage of cleft palates of the total fetuses examined in this group.
eTCDD given SC in DMSO; data of Courtney and Moore (13).
d TCDD given orally in rape seed oil, data of Neubert and Dillmann (14).
September 1973 73compared. Table 5 gives, in addition, the
tan a calculated from these curves as well
as the dose range required for increasing
the teratogenic effect from 2%o (just signi-
ficantly over the controls) to 50%o (probit
3 to 5).
FIGURE 5. Dose-response relationship observed after
single doses of different cleft palate-inducing
drugs. All drugs were given on day 13 of preg-
nancy. TCDD and 2,4,5-T were given per stomach
tube in rape-seed oil; 6-AN, dexamethasone, and
cyclophosphamide were injected subcutaneously.
Each point represents the frequency observed in
the fetuses from at least 12 litters, at the lower
dose range of at least 20 and generally about 30
litters. The data are given as percentage of the
total fetuses evaluated at the dose specified. Tan
a values of the dose-response curves are given
in Table 5; threshold doses derived from these
curves are given in Table 6.
Of the drugs tested, 6-aminonicotinamide
(6-AN), a teratogen extensively studied
biochemically as well as micromorphological-
ly in our laboratory (17-20) shows the larg-
est increase in cleft palate frequency with
increasing doses (log dose), while 2,4,5-T
shows the smallest. A dose-response curve
of intermediate steepness is obtained when
the effect of TCDD or of dexamethasone or
cyclophosphamide (Endoxan) is plotted a-
gainst the dose given. The dose required for
producing a 10%'o effect with the various
teratogens differs by more than four orders
ofmlagnitude!
Embryotoxic Effects Observed after Ap-
plication of TCDD Together with Other
Teratogens
Special emphasis was given to experiments
Table 5. Dose-response relationship with five cleft
palate-inducing drugs.'
tan a
of dose-
response
Increase in dose
necessary to in-
crease effect
from probit 3
to 5 (2%o to
EDso
(cleft
palate),
Drug curve 50% effect) mg/kg
6-AN 7.6 1.3x 10
TCDD 2.3 3x 0.040
Endoxan 1.5 5x 60b
Dexa-
meth-
asone 1.4 6x 20
2,4,5-T 0.8 lx 2000? b
a All drugs were given to the mice as a single
dose on day 13 of pregnancy, (evaluation of
the data shown in Fig. 5).
bNo 50%o effect obtained; value extrapolated.
in which TCDD was combined with other
teratogens. We believe that such combina-
tion studies may serve several purposes.
First, very little is presently known regard-
ing the teratogenic effect of drug combina-
tions, despite the fact that single compounds
very rarely act on an organism, either under
ambient environmental conditions or during
treatment. Therefore, information on the
chance of potentiating effects and the pos-
sible health hazards of combined drug ac-
tions on embryonic development is urgently
needed. Also, almost no information is avail-
able today on the possibility of synergistic
action of two or more drugs in producing
an impairment of embryonic development
which cannot be induced, even by high
doses, by either substance alone. Informa-
tion available from studies with carcinogens
suggests that the likelihood that a certain
drug will induce special teratogenic ef-
fects may be greatly increased by varying
nutritional factors (e.g. vitamins, protein
uptake, heavy metal concentrations) or by
blocking certain metabolic pathways.
When designing experiments in which the
teratogenic effect of combined drug actions
is to be evaluated, several possibilities have
to be considered. (1) Both (or all) drugs
may be given simultaneously over an extend-
ed period of time. This has the advantage
that all substances act on the target tissue
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development. The disadvantage of such an
experimental setup may lie in the secondary
or less interesting effects of the drugs pro-
duced outside of the critical period (e.g.,
embryolethal effects) which could mask
the teratogenic effect to be evaluated. (2)
Both (or all) drugs are given only once,
but at the same time. This gives more favor-
able conditions for evaluating the mechanism
of action. However not all of the drugs may
get the chance to act at the most sensitive
phase. (3) Both (or all) drugs are given
only once, but in sequence, each at the optimal
phase of its effect. The advantages and dis-
advantages of this experimental design are
obvious.
Each of these experimental designs has
advantages when studying special problems.
Each one has practical as well as theoretical
implications. We feel that in the long run
all the three models have to be tested in
order to allow an exact elucidation of tera-
togenic effects of drug combinations. In the
present paper we present the results of some
experiments performed with TCDD combi-
nations by use of experimental designs 1 and
2.
Cleft palate frequency induced by a com-
bination of TCDD and 2,4,5-T given during
days 6 and 15 of gestation-Studies with
combinations of TCDD and 2,4,5-T were per-
formed first, since an effect of this drug
combination was of special interest. Large
experimental series performed in various
laboratories with 2,4,5-T preparations con-
taminated with dioxins to a very different ex-
tent led to such variable results that studies
with a clear-cut combination of compounds
were warranted.
Figure 6 shows the results of experiments
in which a teratogenically active dose of
2,4,5-T (60 or 100 mg/kg) was combined
with a threshold dose of TCDD or even much
smaller doses.
Although we are completely aware of the
fact that there is no "threshold dose" we
use this term for convenience to indicate
that dose (derived from a dose-response
curve) which gives just no significant in-
crease of cleft palate frequency over that
of the controls, when 300-500 fetuses from
treated mice and 2000 fetuses from controls
are evaluated (1.5% cleft palate frequency,
0.7% seen with controls; under our experi-
mental conditions, x2 > 3.5).
A clear-cut effect is seen on combining
60 mg/kg 2,4,5-T with the "threshold dose"
of TCDD (2 ug/kg), and a detectable poten-
tiation is produced even with 1/10 of this
Table 6. Just nonteratogenic doses of the drugs used in our combination experiments
(threshold doses).8
TCDD, ,ug/kg 2,4,5-T mg/kg 6-AN,
mg/kg
Day 13 Day 6-15 Day 13 Day 6-15 Day 13
Dexa-
meth-
asone,
mg/kg
Day 13
Endoxan,
mg/kg
Day 13
"Just teratogenic" dose b 15 3 250 40 7.5 4 15
"just nonteratogenic" dose 12 2 150 30 7 2 10
"Threshold dose" as
fraction of ED50 C 1/3 1/13d 7/10 1/10 1/6 d
a All doses were derived from dose-response curves, with at least 300 fetuses evaluated at the low dose
levels. The data refer to single doses given on day 13 of pregnancy.
bThe "just teratogenic" dose gives the lowest dose found to produce a significant effect (x' > 3.5)
under our experimental conditions, 300-500 fetuses being evaluated per dose.
Although we are aware of the fact that a "threshold dose" cannot be determined accurately, we use
this term for the convenience of planning our combination experiments. In this paper this term is
defined as the lowest dose found under our experimental conditions (300-500 fetuses) not to be able
to produce an effect significantly different from the controls (2000 fetuses evaluated). For a more
accurate definition this dose is also characterized as a fraction of the ED50.
d Fetal ED50 extrapolated since this dose is toxic to maternal organism or fetolethal.
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FIGURE 6. Cleft palate frequency in mice produced
by a combination of TCDD and 2,4,5-T. Both drugs
were given in the doses indicated (mg/kg for
2,4,5-T and /ag/kg for TCDD) during the days
6-15 of pregnancy once daily by stomach tube.
In each group 20 litters were evaluated. The data
are given as number of fetuses per litter (M).
The effect produced by 60 mg/kg 2,4,5-T + 2
,ug/kg TCDD is highly significant, that produced
by 100 mg/kg 2,4,5-T + 0.1 ,ug/kg TCDD just
significant (P = 0.01).
dose of TCDD. This combination would cor-
respond to a "contamination" of 3.3 ppm.
When the dose of 2,4,5-T-and thereby the
effect produced by this compound alone- is
increased, even smaller doses of TCDD (0.1
,ug/kg) lead to a detectable increase in the
frequency of malformations. This combina-
tion would correspond to about 1 ppm. No
significant potentiation can be observed when
the dose of TCDD is lowered by another fac-
tor of 5 (to 0.02 ,1g/kg), corresponding to 0.2
ppm.
Although in such an experimental setup
an effect by as little as 50 ng/kg TCDD can
be detected, these data clearly show that a
potentiating effect in this system cannot
be obtained even if highly teratogenic doses
of 2,4,5-T are used-with a combination con-
taining less than 0.5 ppm TCDD.
Further experiments were performed to
get some information on what doses of TCDD
are required to induce a detectable effect
when just "nonteratogenic" doses of 2,4,5-T
are used.
Under the conditions specified, 30 mg/kg
was about a threshold dose. When this dose
of 2,4,5-T is combined with 2 jug/kg TCDD
FIGURE 7. Cleft palate frequency in mice produced
by a combination of TCDD and 2,4,5-T. Experi-
mental conditions as in Fig. 6. The effects ob-
served with both 15 mg/kg 2,4,5-T + 2 ,ug/kg
TCDD and with 30 mg/kg 2,4,5-T + 2 ,tg/kg
TCDD are highly significant (P < 0.0027).
(also a threshold dose), 66 ppm, a clear-cut
potentiation can be observed (Fig. 7). The
same dose of TCDD (2 jug/kg) increases the
cleft palate frequency over the background
also when half the 2,4,5-T dose is used (15
mg/kg), corresponding to 133 ppm. But 1/10
of the TCDD dose (0.2 jug/kg) does not in-
duce any detectable effect with either
of the doses 2,4,5-T used in this experi-
mental series. This suggests that when just
nonteratogenic doses of 2,4,5-T are used,
there is no effedt with the system used if
less than 10-20 ppm TCDD is present.
The results obtained with our experimental
setup may give too high values since we
have used neither the most sensitive strain
of mice nor the malformation seen with the
lowest dose in this strain (kidney abnor-
malities). It is furthermore interesting that
with none of the combinations mentioned
an increased fetomortality could be observed.
Cleft palate frequency induced by giving a
combination of TCDD and other teratogens
simultaneously on day 13 of gestation.-In
these studies all the teratogens were given
only once. Day 13 was chosen as the most
convenient time of gestation (Fig. 4). In
these studies, therefore, two of theteratogens
were not given at the most sensitive phase
of development.
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ISince 2,4,5-T cannot be considered a very
powerful teratogen we have studied the pos-
sibility of an occurrence of a potentiation
when TCDD is combined with other cleft
palate-inducing teratogens. Special empha-
sis was placed on the differences in dose
response characteristics for these agents. Re-
sults of such experimental series are com-
piled in Figure 8. In this study the cleft
palate frequency was measured when just
nonteratogenic doses (threshold doses) of the
teratogens were combined with a threshold
dose of TCDD (12 ,pg/kg).
b'IGURE 8. Cleft palate frequency induced by drug
combinations. All drugs were given once on day
13 of pregnancy (TCDD and 2,4,5-T in rape-seed
oil by stomach tube, all other drugs subcutan-
eously) at the doses indicated, which represent
the just nonteratogenic (or threshold) doses as
explained in Table 6. At least 12 litters were
evaluated in each group. The data are given as
percentage of the total fetuses evaluated per
group (probit scale).
It can be seen that a potentiation occurs
after a treatment with all the teratogens
studied. The degree of potentiation varied
somewhat; a combination of TCDD with
2,4,5-T resulted in about 15%o cleft palate and
about the same frequency was observed with
a combination of TCDD with dexamethasone.
With a combination of TCDD and 6-AN
almost 60%o of the mouse fetuses showed
this teratogenic effect. It is interesting that
the dose-response curve obtained with 6-
AN is very steep when compared with those
for 2,4,5-T or dexamethasone.
These data as well as data obtained with
other combination (21) suggest that an espe-
cially pronounced potentiation is to be ex-
pected when two drugs showing both a rath-
er steep dose-response curve are combined,
while less potentiation is to be expected
from the combined action of two drugs re-
vealing a flat dose-response relationship.
Of course, this prediction only holds as long
as each drug does not act by interfering
with the metabolism of the other. Accord-
ingly, the TCDD-2,4,5-T pair should be ex-
pected to give a moderate degree of potentia-
tion in the assay system usedhere.
Cleft palate frequency after treatment
with a single dose of more than two terato-
gens.-We have, furthermore, performed
studies to elucidate the possibility of TCDD
potentiating the teratogenic action of other
drugs when several such teratogens are given
simultaneously in "subthreshold" doses. For
these experiments all the drugs were given
in doses of about half of the just non-
teratogenic dose.
Figure 9 shows that neither a combination
of 6-AN and dexamethasone nor the com-
bination ofthe three drugs 6-AN, dexametha-
sone, and 2,4,5-T at this dose leads to an
effect significantly different from that ob-
served in controls. When TCDD is added
to this drug combination as a fourth drug,
however, at about half of the just nontera-
ogenic dose (6 pg/kg), a pronounced effect
can be demonstrated. The cleft palate fre-
quency is about 30%o.
From these combination experiments and
with regard to the model studied we wish to
draw the following conclusions.
(1) When doses of TCDD much lower than
the threshold dose are combined with tera-
togenic doses of drugs that are able to pro-
duce the same teratogenic effect, a potentia-
tion may be expected, even with doses of
TCDD as low as 1/20 to 1/50 of the threshold
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FIGURE 9. Cleft palate frequency induced by drug
combinations. Experimental conditions as in Fig-
ure 8, except that more than two drugs were
given simultaneously in some of the experiments.
The doses given represent about half the threshold
dose, as defined in Table 6.
dose (2 ug/kg).
(2) When just nonteratogenic doses of
TCDD are combined with just nonteratogenic
(threshold) doses of drugs which are able
to produce the same teratogenic effect, a
potentiation may be expected, the degree of
which depends on tan a of the dose-response
curve ofthe teratogens used.
(3) When two teratogenic drugs are com-
bined at half the level of the threshold doses
or lower, a significant effect is not to be
expected unless both the teratogens exhibit
very steep dose-response curves. In the case
of TCDD a just significant effect is obtained
with 6-AN but not in combination with 2,4,5-
T, dexamethasone, or Endoxan.
(4) When TCDD at half the level of the
threshold dose is combined simultaneously
with three other teratogens, all at this dose,
a clearcut potentiation is observed.
(5) Our results do not give any indication
that in the system used TCDD in a dose of
about 1/10 of the threshold dose would be
able to induce a teratogenic effect, even in
combination with up to three other tera-
togens simultaneously present in doses of
half the threshold dose or lower.
All the foregoing conclusions are only
valid as long as the drug metabolism of any
of the teratogens used is not drastically
altered duringthe combination studies.
Materials and Methods
For all experiments performed in this
laboratory mice of the strain NMRI (pur-
chased from Schwenke & Co., Bad Nauheim,
Germany) weighing 29 ± 3 g were used.
The animals were mated (20 females with
10 males per cage) for 2 hr and subsequently
checked for vaginal plugs. The 24-hr period
following the mating (8 A.M.) was called
day 0 of pregnancy. Altromin R and tap
water were given ad libiturn.
The animals were sacrificed on day 18 of
pregnancy and the number of viable fetuses
was counted. Resorbed fetuses were regarded
as dead. Litters with less than five im-
plantation sites were not included in the
evaluation. The average litter size was 11.1
1 1.3 with this strain.
The results presented in this paper are
based on the evaluation of about 1000
treated pregnant mice (ca. 11000 fetuses)
and about 250 controls (ca. 2800 fetuses).
Embryotoxic effects have been evaluated
in this paper as frequency per single litter
or alternatively as percentage of the total
of fetuses examined. Although the litter
should be considered the experimental unit
for statistical evaluations in teratological
studies we feel that a calculation of the
embryotoxic effects based on the total num-
ber of fetuses examined is justified, since a
closer analysis of our data always has re-
vealed that the occurrence of embryotoxic
effects is distributed randomly (14). In all
general calculations of our data litters show-
ing more than 75%5 resorptions have not
been included but were listed separately.
Embryolethal and teratogenic effects were
statistically evaluated from the total per-
centages or from the frequencies occurring
in each litter (M ± S.D.) by using a t-test
(22) or a X2-test.
Pure TCDD (Lot No. 851:142-26) was
kindly provided by the Dow Chemical Co.,
Midland, Michigan, U.S. This extremely toxic
substance was handled with utmost care. The
purity (gas chromatographic analysis) in-
Environmental Health Perspectives 78dicated was 98.6%o. The drug was dissolved
in acetone or chloroform and vigorously
mixed with rape-seed oil. Doses of 0.1 ml/10
g mouse were given by stomach tube.
Pure 2,4,5-T (Lot SHG) was kindly pro-
vided by C.H. Boehringer, Ingelheim, Ger-
many. The dioxin content indicated was <
0.02 ppm. Since this preparation was syn-
thesized by a special procedure it may be
considered dioxin-free. The drug was dis-
solved in rape-seed oil by gently warming to
400 C and given to the mice by stomach tube
(0.1 ml/10 g mouse). When 2,4,5-T and
TCDD were given together, stock solutions
were mixed before giving the solution (oil)
to the experimental animals at a dose of
0.1 ml/10 g.
6-AN was purchased from Calbiochem
(U.S.)
Dexamethasone (Fortecortin) was a gift
of E. Merck, Darmstadt, Germany. It was
given to the mice in aqueous solution by
subcutaneous injection.
Pure cyclophosphamide (Endoxan) was
a gift of Asta-Werke, Brackwede, Germany.
The drug was given to the mice in aqueous
solution by subcutaneous injection.
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